Nuclear Medicine Communications最新文献

{"title":"Assessment of quantitative staging PET/computed tomography parameters using machine learning for early detection of progression in diffuse large B-cell lymphoma.","authors":"Ayşegül Aksu, Anilcan Us, Kadir Alper Küçüker, Şerife Solmaz, Bülent Turgut","doi":"10.1097/MNM.0000000000002023","DOIUrl":"10.1097/MNM.0000000000002023","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the role of volumetric and dissemination parameters obtained from pretreatment 18-fluorodeoxyglucose PET/computed tomography (18F-FDG PET/CT) in predicting progression/relapse in patients with diffuse large B-cell lymphoma (DLBCL) with machine learning algorithms.</p><p><strong>Methods: </strong>Patients diagnosed with DLBCL histopathologically, treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, and followed for at least 1 year were reviewed retrospectively. Quantitative parameters such as tumor volume [total metabolic tumor volume (tMTV)], tumor burden [total lesion glycolysis (tTLG)], and the longest distance between two tumor foci ( Dmax ) were obtained from PET images with a standard uptake value threshold of 4.0. The MTV obtained from the volume of interest with the highest volume was noted as metabolic bulk volume (MBV). By analyzing the patients' PET parameters and clinical information with machine learning algorithms, models that attempt to predict progression/recurrence over 1 year were obtained.</p><p><strong>Results: </strong>Of the 90 patients included, 16 had progression within 1 year. Significant differences were found in tMTV, tTLG, MBV, and Dmax values between patients with and without progression. The area under curve (AUC) of the model obtained with clinical data was 0.701. While a model with an AUC of 0.871 was obtained with a random forest algorithm using PET parameters, the model obtained with the Naive Bayes algorithm including clinical data in PET parameters had an AUC of 0.838.</p><p><strong>Conclusion: </strong>Using quantitative parameters derived from staging PET with machine learning algorithms may enable us to detect early progression in patients with DLBCL and improve early risk stratification and guide treatment decisions in these patients.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"972-979"},"PeriodicalIF":1.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144529170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of Tc-99m-macroaggregated albumin administration on pulmonary vascular resistance.","authors":"Deborah Pencharz, Rosalind Pliszka, Adrien Michael Peters","doi":"10.1097/MNM.0000000000002024","DOIUrl":"10.1097/MNM.0000000000002024","url":null,"abstract":"<p><p>For patients with pulmonary hypertension, reduced administered activity of Tc-99m-macroaggregated albumin (MAA) is recommended for ventilation/perfusion scintigraphy. Although it is stated that MAA particles embolise in pulmonary capillaries, of which there are ~300 billion, they embolise in pulmonary arterioles, of which there are far fewer. This aim of this study, therefore, is to address the recommendation's validity. Using morphometric data of Horsfield, we estimated pulmonary vascular resistance (PVR) increments resulting from the administration of 100, 200, and 400 k MAA particles. We assumed two particle size distributions: one skewed left toward small particles and the other skewed right. MAA-induced PVR increments were also estimated for pulmonary vascular beds depleted by disease. Administration of 100, 200, and 400 k particles with left-skewed size distribution increases PVR by 2.7, 5.7, and 12.2%, respectively. Corresponding right-skewed values are 6.2, 13.5, and 32.4%. Following 25, 50, and 75% pulmonary vascular ablation, 200 k left-skewed particles increase PVR by 7.8, 12.2, and 29%, respectively, and right-skewed by 19, 32, and 109%, on top of PVR already increased from disease. Particle size distribution is important. Less than 200 k MAA particles should be administered to patients with pulmonary hypertension.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"1013-1017"},"PeriodicalIF":1.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144637704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical evaluation of the novel FAP-targeting PET tracer 68 Ga-XT117 in solid tumors, its synergistic role, and comparison with 18 F-FDG.","authors":"Zhihui Shen, Qingxiao Li, Jinglan Zhou, Xiaojun Zhang, Jingbin Song, Huijuan Ji, Shasha Sun, Kuan Wang, Ruimin Wang","doi":"10.1097/MNM.0000000000002019","DOIUrl":"10.1097/MNM.0000000000002019","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the diagnostic performance of the novel fibroblast activation protein-targeting PET tracer 68 Ga-XT117 compared with 18 F-fluorodeoxyglucose ( 18 F-FDG) in solid tumors.</p><p><strong>Methods: </strong>This single-center, prospective, open-label study enrolled 14 patients with solid tumors. Participants received 68 Ga-XT117 at different doses (3, 5, or 7 mCi) and underwent PET/CT scans at multiple time points. Image quality was assessed using maximum standardized uptake value and tumor-to-background ratio. All patients underwent both 68 Ga-XT117 and 18 F-FDG PET/CT within 1 week for head-to-head comparison.</p><p><strong>Results: </strong>68 Ga-XT117 demonstrated optimal imaging quality at a dose of 5 mCi with an acquisition time of 40-min postinjection. In the head-to-head comparison, 68 Ga-XT117 detected 137 lesions and 18F-FDG detected 138 lesions overall. 68 Ga-XT117 showed improved detection of primary lesions (23 vs. 20) and lymph node metastases (13 vs. 6) compared to 18 F-FDG. The tracer exhibited significantly higher uptake in sarcomas compared to gastrointestinal tumors ( P = 0.014). Additionally, 68 Ga-XT117 showed advantages in detecting certain lesion subtypes, particularly lymph node metastases, and bone lesions. The administration of 68 Ga-XT117 was well tolerated, and no adverse events were observed or reported during the study.</p><p><strong>Conclusion: </strong>68 Ga-XT117 demonstrates favorable diagnostic performance, particularly in low-metabolic tumors, with good safety and optimal imaging characteristics. The tracer shows a complementary value to 18 F-FDG in lesion detection. Further prospective studies are warranted to validate the clinical significance of the additionally detected lesions.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"949-958"},"PeriodicalIF":1.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144626806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postmarketing safety surveillance of 177 Lu-DOTA-TATE (LUTATHERA): an observational, pharmacovigilance study leveraging FAERS database.","authors":"Xinhua Wu, Jing Liao, Wei Chen, Jianwei Dou","doi":"10.1097/MNM.0000000000002015","DOIUrl":"10.1097/MNM.0000000000002015","url":null,"abstract":"<p><strong>Objective: </strong>177 Lu-DOTA-TATE (LUTATHERA) is a crucial radiopharmaceutical in neuroendocrine tumor therapy, yet real-world long-term safety data across diverse populations remain limited. This study aims to comprehensively assess the postmarketing safety of LUTATHERA using a real-world pharmacovigilance database.</p><p><strong>Methods: </strong>We conducted an observational study using the US Food and Drug Administration's Adverse Event Reporting System (FAERS) database from the first quarter of 2018 to the third quarter of 2024. Reports were filtered for LUTATHERA as the primary suspect. The characteristics and onset time of LUTATHERA-associated adverse events were analyzed. The disproportionality analysis via reporting odds ratio (ROR) and Bayesian confidence propagation neural network was employed to identify significant adverse event signals associated with LUTATHERA.</p><p><strong>Results: </strong>A total of 4058 reports identified with LUTATHERA as the primary suspected drug. LUTATHERA was linked to increased risks in in general disorders, gastrointestinal, hematological, metabolic, hepatobiliary, and endocrine systems. Common adverse events like nausea, thrombocytopenia, and anemia aligned with clinical trial data. Novel and serious signals such as intestinal obstruction [ROR = 5.62, information component (IC) = 2.49], gastrointestinal hemorrhage (ROR = 2.84, IC = 1.50), carcinoid heart disease (ROR = 571.03, IC = 8.93), and esophageal varices hemorrhage (ROR = 11.92, IC = 3.57) were also identified. LUTATHERA-associated adverse events typically occurred within 2 months, with a median onset of 54 days.</p><p><strong>Conclusion: </strong>This study enhances understanding of LUTATHERA's safety profile, offers clinicians valuable data, and advocates continuous pharmacovigilance. Continuous pharmacovigilance and potential label updates are recommended.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"905-912"},"PeriodicalIF":1.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144529173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of disease severity in Sjögren's syndrome using semiquantitative parameters on salivary gland scintigraphy.","authors":"Tejasvini Singhal, Parneet Singh, Girish Kumar Parida, Ashique Rehman, Pramit Kumar, Kanhaiyalal Agrawal, P Sai Sradha Patro","doi":"10.1097/MNM.0000000000002020","DOIUrl":"10.1097/MNM.0000000000002020","url":null,"abstract":"<p><strong>Introduction: </strong>Sjögren's syndrome is a chronic autoimmune disease characterized by lymphocytic infiltration and destruction of exocrine glands. Sjögren's syndrome characteristically involves salivary glands with the presence of xerostomia in the majority (>93%) of patients. The severity of xerostomia can vary from mild to severe and debilitating. Labial histopathology and antinuclear antibodies (ANA) are commonly used in the diagnosis of Sjögren's syndrome but do not correlate well with disease severity. Tests available for objective assessment of disease severity include sialometry and salivary gland scintigraphy (SGS). This study aims to correlate the severity of xerostomia with semiquantitative parameters on SGS.</p><p><strong>Materials and methods: </strong>On the basis of clinical symptoms, the severity of xerostomia was graded into mild, moderate, and severe. Semiquantitative parameters (maximum uptake and excretion fractions) for all salivary glands were calculated on SGS. Spearman's correlation coefficients were calculated to assess correlation with clinical disease severity.</p><p><strong>Results: </strong>One-hundred thirteen patients (94 females and 19 males) with a median age of 39 years (range: 4-85 years) were included. Of these, 74 had mild, 28 had moderate, while only 11 had severe disease. There was a statistically significant difference between the mean values of maximum uptake and excretion fractions across the three severity groups ( P < 0.05).</p><p><strong>Conclusion: </strong>Semiquantitative parameters on SGS show a reduction with an increase in the severity of xerostomia. In addition, maximum uptake and excretion fractions correlated well with the severity of xerostomia of Sjögren's syndrome, whereas ANA levels showed no significant correlation with disease severity. SGS can serve as an objective parameter of clinical severity of xerostomia, which is otherwise difficult to determine clinically.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"923-928"},"PeriodicalIF":1.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144626805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical value of multiparameters of 2-[ 18 F]-fluoro-2-deoxy-glucose PET/MRI in tumor/lymph node staging of esophageal squamous cell carcinoma.","authors":"Yunbo Li, Junyan Wang, Jinzi Hui, Wei Zhang, Wei He, Yixin Wei, Long Jin, Peng Yuan, Menghui Yuan","doi":"10.1097/MNM.0000000000002013","DOIUrl":"10.1097/MNM.0000000000002013","url":null,"abstract":"<p><strong>Purpose: </strong>We aimed to determine the role of integrated 2-[ 18 F]-fluoro-2-deoxy-glucose ( 18 F-FDG) PET/MRI in preoperative T and N staging and prognosis of esophageal squamous cell carcinoma (ESCC).</p><p><strong>Materials and methods: </strong>The analysis was conducted on 66 ESCC patients who accepted 18 F-FDG-PET/MRI examinations per-operatively. We select the primary lesion as the region of interest to evaluate the diagnostic efficiency of T and N staging. Univariate and stepwise multivariate logistic regression models were performed to determine the T and N staging factors, and we established the optimal prediction model by using the Akaike information criterion. Finally, Cox regression was used for the early recurrence analyses.</p><p><strong>Results: </strong>The total lesion glycolysis (TLG), metabolic tumor volume (MTV), minimum apparent diffusion coefficient (ADC min ), and mean apparent diffusion coefficient (ADC mean ) were significant in univariate analysis with T staging. None of the parameters were significant in the univariate analysis with N staging. Cox regression validated that this model-combining TLG (>47.5), MTV (>9.4 cm 3 ), ADC min (<1.49 × 10 -3 mm 2 /s), and ADC mean (<1.68 × 10 -3 mm 2 /s)-was the sole predictor significant associated with early tumor recurrence. Notably, no association was found between any single variable and early tumor recurrence.</p><p><strong>Conclusion: </strong>Integrated 18 F-FDG PET/MRI is feasible for preoperative T and N staging of ESCC. The optimal model is composed of TLG, MTV, ADC min, and ADC mean -all parameters derived from 18 F-FDG-PET/MRI-which not only provide valuable information for T staging but also predict early recurrence within the first postoperative year.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"929-938"},"PeriodicalIF":1.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12422628/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144584487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of tumor dissemination feature based on baseline 18F-FDG PET/CT in patients with newly diagnosed multiple myeloma.","authors":"Yue-Hong Guo, Ying Tian, Jing-Wei Huang, Ai-Jun Liu, Min-Fu Yang","doi":"10.1097/MNM.0000000000002059","DOIUrl":"https://doi.org/10.1097/MNM.0000000000002059","url":null,"abstract":"<p><strong>Objectives: </strong>We evaluated the prognostic value of the new 18F-fluorodeoxyglucose PET/computer tomography (18F-FDG PET/CT) parameter reflecting the spread of the tumor, the largest distance between two lesions (Dmax), and compared the predictive power of the new parameter with other parameters in newly diagnosed multiple myeloma (NDMM) patients.</p><p><strong>Methods: </strong>This retrospective study included 58 consecutive patients diagnosed with NDMM. 18F-FDG parameters [maximum standardized uptake value, metabolic tumor volume (MTV), and Dmax] and clinical data were analyzed for event-free survival (EFS). Univariate and multivariate analyses were performed using the Cox proportional hazards model, while survival outcomes were assessed via Kaplan-Meier curves.</p><p><strong>Results: </strong>The median length of follow-up was 42 months (interquartile range, 18-62 months). Univariate analysis identified elevated serum calcium, elevated serum creatinine, MTV > 102.54 cm3, Dmax > 0.44 m, Dmax normalized by body height (Dmaxbh) > 0.27, Dmax normalized by body surface area (Dmaxbsa) > 0.24 m-1, and International Staging System stage as relevant prognostic factors for EFS (P < 0.1). Only Dmax > 0.44 m was found to be an independent prognostic factor for EFS on multivariate analysis (P = 0.047).</p><p><strong>Conclusion: </strong>The new PET parameter of Dmax, reflecting myeloma dissemination, has been shown the independent prognostic value in NDMM patients. This preliminary finding warrants further investigation.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145186449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility of real-time monitoring for administered activity during Lu-177 infusion by imaging the administration site using a pinhole gamma camera: a Monte Carlo study.","authors":"Kohei Nakanishi, Seiichi Yamamoto, Naotoshi Fujita, Kenta Miwa, Ryuichi Nishii","doi":"10.1097/MNM.0000000000002054","DOIUrl":"https://doi.org/10.1097/MNM.0000000000002054","url":null,"abstract":"<p><strong>Objectives: </strong>Using personalized treatment with Lu-177-labeled radiopharmaceuticals, rather than using a fixed activity of 7.4 GBq, the administered radioactivity is adjusted in each patient. Achieving precise control of the administered activity would be possible during Lu-177 infusion if real-time monitoring techniques were possible. However, these techniques are not currently available. In this study, we used Monte Carlo simulations to simulate imaging of the administration site in an arm phantom with a pinhole gamma camera to explore the feasibility of achieving real-time monitoring and control of the administered activity during infusion.</p><p><strong>Methods: </strong>We used the Geant4 toolkit to simulate a compact gamma camera. We simulated the basic performance of the camera within an energy window of 208 keV ± 10% and the imaging of an arm phantom to evaluate the feasibility of visualizing and quantifying the inflow of Lu-177-labeled radiopharmaceutical activity.</p><p><strong>Results: </strong>The spatial resolution with the 1.0-mm pinhole collimator for Lu-177 was 1.8 mm full width at half maximum (FWHM) at 50 mm, whereas it was 1.2 mm FWHM for the 0.5-mm pinhole collimator. Our gamma camera captured the activity of Lu-177 in a 3.0-mm diameter vessel within the arm phantom, achieving measurements in only 1 min. The maximum values among the mean estimation errors of the administered activity were 0.73% and -3.53% for the 1.0 and 0.5-mm pinhole collimators, respectively, both occurring within the initial 1 min.</p><p><strong>Conclusion: </strong>Monte Carlo simulations demonstrated the feasibility of real-time monitoring of administered activity during Lu-177 infusion by imaging the administration site with our pinhole gamma camera.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145186466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lung-to-heart ratio on thallium-201 myocardial perfusion imaging in patients with chronic obstructive pulmonary disease.","authors":"Kuan-Yin Ko, Chia-Ju Liu, Yi-Hsien Chou, Chi-Lun Ko","doi":"10.1097/MNM.0000000000002052","DOIUrl":"https://doi.org/10.1097/MNM.0000000000002052","url":null,"abstract":"<p><strong>Background: </strong>In thallium-201 (Tl-201) stress myocardial perfusion imaging (MPI), elevated lung-to-heart ratio (LHR) can help to predict adverse cardiac events and identify coronary artery disease. However, few studies have evaluated the LHR values on Tl-201 MPI in patients with chronic obstructive pulmonary disease (COPD).</p><p><strong>Objective: </strong>To examine whether LHR in COPD may be altered, considering the combined effects of hypoxia, inflammation, and capillary loss.</p><p><strong>Methods: </strong>We retrospectively evaluated patients with normal Tl-201 pharmacologic stress MPI, no adverse cardiac events in the subsequent 2 years, and pulmonary function tests, coronary angiography, and echocardiography results obtained within 6 months. Patients with COPD (study group) were matched 1:1 by sex and age to controls with normal pulmonary function (control group). Subgroups within the study group were established based on COPD severity determined by spirometry. MPI images were interpreted using a 17-segment american heart association (AHA) model and a 0-4-point scale. LHR and right ventricle/left ventricle (RV/LV) ratios were also documented.</p><p><strong>Results: </strong>Patients with severe COPD exhibited lower poststress LHR values than those with mild-to-moderate COPD. Compared with the control group, the moderate COPD group displayed higher stress LHR, stress RV/LV ratio, and tricuspid regurgitation maximum pressure gradient (TRmaxPG) values. Moreover, poststress LHR showed a positive correlation with the stress RV/LV ratio and TRmaxPG value. These findings were statistically significant (P < 0.05).</p><p><strong>Conclusion: </strong>In Tl-201 pharmacologic stress MPI, our study suggests a nuanced relationship between COPD severity and LHR, emphasizing the need to reconsider normal LHR thresholds in COPD. Larger studies are warranted to validate and expand upon these findings.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145086830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An assessment of conformance to structured reporting framework in 68Ga prostate-specific membrane antigen PET/computed tomography for prostate cancer staging.","authors":"Jagrati Chaudhary, Sanjay Kumar, Param Dev Sharma, Kunhi Parambath Haresh, Rakesh Kumar, Chandan J Das, Ranjit Kumar Sahoo, Seema Kaushal, M Kalaivani, Anil Kumar Pandey","doi":"10.1097/MNM.0000000000002048","DOIUrl":"https://doi.org/10.1097/MNM.0000000000002048","url":null,"abstract":"<p><strong>Background: </strong>68Ga prostate-specific membrane antigen (PSMA) PET/computed tomography (CT) plays a critical role in prostate cancer management. Most clinical reports, however, remain unstructured, increasing the risk of omitting essential diagnostic information. Although standardized frameworks such as PROMISE (Prostate Cancer Molecular Imaging Standardized Evaluation) have been proposed to improve consistency, real-world adherence remains variable. This study assessed the adequacy of 68Ga PSMA PET/CT reports and evaluated their alignment with PROMISE recommendations.</p><p><strong>Methods: </strong>A total of 189 68Ga PSMA PET/CT reports were retrospectively reviewed and scored based on the presence (1) or absence (0) of six diagnostic elements: primary tumor localization, PSMA uptake intensity, lymph node involvement, bone metastases, visceral metastases, and seminal vesicle involvement. Reports were classified as clinically adequate (score ≥5), partially adequate (3-4), or inadequate (<3). A one-sample z test assessed whether the proportion of adequate reports met a 90% benchmark (α = 0.05). Chi-square tests evaluated differences in reporting frequencies across elements.</p><p><strong>Results: </strong>None of the reports (0%) were inadequate. Of 189 reports, 95 (50.3%) were clinically adequate (score ≥5) and 94 (49.7%) were partially adequate (score 3-<5), with a significant overall adequacy rate (P < 0.0001). A notable gap existed between documentation of seminal vesicle involvement and prostate size (P < 0.0001). Despite consistent reporting of anatomical localization and molecular imaging tumour, node, metastases (miTNM) classification, key elements were often missing, including PSMA uptake metrics, lesion size, nodal features, CT parameters, imaging protocol, and reader confidence.</p><p><strong>Conclusion: </strong>In this single-center study, free-text 68Ga PSMA PET/CT reports were adequate for clinical needs but demonstrated only partial conformity to the PROMISE framework.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145086792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}